BioMarin Presents New Phase 3, 4-Year Data Underscoring Long-Term Safety And Efficacy Of ROCTAVIAN At International Society On Thrombosis And Haemostasis 2024 Congress In Bangkok, Thailand, June 22-26, 2024
Portfolio Pulse from Benzinga Newsdesk
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced new data supporting the long-term safety and efficacy of ROCTAVIAN, a hemophilia gene therapy, to be presented at the ISTH 2024 Congress. The data shows durable bleed control and sustained Factor VIII expression four years post-infusion, along with a meaningful impact on health-related quality of life.
June 07, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioMarin's new data on ROCTAVIAN, showing long-term safety and efficacy, will be presented at ISTH 2024. This could positively impact the stock price due to the promising results and potential market confidence.
The presentation of long-term data showing the safety and efficacy of ROCTAVIAN at a major international congress is likely to boost investor confidence in BioMarin's product pipeline, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100